Jamieson Wellness Inc. Announces Filing of Management Information Circular for Annual Meeting of Shareholders

Jamieson Wellness Inc. (" Jamieson Wellness " or the " Company ") (TSX: JWEL) announced today that the Company has filed its management information circular (" Circular ") and related materials (together with the Circular, the " Meeting Materials ") for the annual meeting of shareholders (the " Shareholders ") of Jamieson Wellness to be held on May 24, 2022 at 2:00 p.m. (Eastern Daylight Time) virtually via live audio webcast at meetnow.globalMZ4D4RR (the " Meeting ").

The Meeting Materials have been filed under Jamieson's profile on SEDAR at www.sedar.com and are also available on the Company's website at www.jamiesonwellness.com .

The Meeting Materials are being mailed to Shareholders to provide information about the business to be conducted at the Meeting, detailed instructions about how to vote shares and how to attend and participate at the Meeting. The Company encourages Shareholders to review the Meeting Materials before voting their shares.

Similar to last year, to proactively address the public health impact of the COVID-19 outbreak, to mitigate the risks to the health and safety of our communities, Shareholders, employees and other stakeholders, and to comply with any applicable public health restrictions limiting indoor events that may be in effect at the time of the Meeting, the Meeting will be held in a virtual only format.

About Jamieson Wellness

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. The Company also offers a variety of natural health solutions through its Progressive, Smart Solutions, Iron Vegan and Precision brands. For more information please visit jamiesonwellness.com .

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

Contact

For questions or assistance with the completion and delivery of proxy materials, please contact Jamieson Wellness' proxy solicitation agent and shareholder communications advisor:

Laurel Hill Advisory Group
1.877.452.7184 toll-free in Canada
+1.416.304.0211 International
assistance@laurelhill.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

JWEL:CA
The Conversation (0)
Scientists examining a sample under a microscope in a lab setting.

Gilead to Acquire Arcellx in US$7.8 Billion Bet on Cancer Therapy

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline.The agreement,... Keep Reading...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...
Pill labeled "GLP-1" on a $100 bill background.

As GLP-1 Brands Go Prime Time, Regulators Flag Growing Illicit Market

At Super Bowl LX, companies behind blockbuster GLP-1 medications spent tens of millions of dollars to court a mass audience. But as brand-name makers and telehealth platforms race to normalize and expand access, regulators on both sides are warning of a parallel surge in counterfeit, compounded,... Keep Reading...
Solvonis Therapeutics

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...

Interactive Chart

Latest Press Releases

Related News